Core Viewpoint - The approval of Weisheng Pharmaceutical's long-acting growth hormone injection marks a significant advancement in the domestic growth hormone market, addressing compliance issues associated with daily injections for children with growth hormone deficiency [1][2]. Industry Overview - The Chinese growth hormone market has surged from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, and is projected to reach 28.6 billion yuan by 2030 [1]. - The long-acting growth hormone market is expected to surpass short-acting products within two years and capture 80% of the total market by 2030 [1]. Competitive Landscape - Existing competitors in the long-acting growth hormone space include Changchun High-tech's Jinsai Pharmaceutical, Teva Biopharma, and Novo Nordisk, with Jinsai and Teva's products already included in the national medical insurance directory for 2025 [2]. - Weisheng's long-acting growth hormone is the only one clinically proven to outperform daily formulations, offering both long-lasting effects and maintaining the natural structure of growth hormone molecules [2]. Product Advantages - Weisheng's long-acting growth hormone can be stored at room temperature below 30 degrees Celsius for up to six months, enhancing convenience for patients compared to other products that require refrigeration [2]. - The pricing strategy for Weisheng's product is anticipated to be higher than currently insured long-acting growth hormones, which have seen significant price reductions due to insurance coverage [3]. Commercial Strategy - Weisheng has partnered with Anke Bio to leverage its extensive commercial experience in the growth hormone sector, focusing on coastal provinces while Anke manages other regions [3]. - The company aims to target private clinics, where a significant portion of growth hormone treatments occur, to reach potential patients effectively [4]. Future Developments - There is potential for the introduction of even longer-acting monthly formulations, with ongoing clinical trials for a novel ultra-long-acting growth hormone [4].